1. The document discusses the association between the HLA-B*1502 gene and carbamazepine-induced severe cutaneous adverse drug reactions in Han Chinese patients. 2. Studies found that HLA-B*1502 screening can effectively reduce the risk of carbamazepine-induced severe cutaneous adverse reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with this gene. 3. Screening for HLA-B*1502 is recommended for Han Chinese patients before initiating carbamazepine treatment to minimize the risk of severe cutaneous adverse reactions.

1. ! HLA-B*1502 F F F
F F F
21 F F
F F
F F ( .)
F F
. . F F
. . . . .
F F F
F F HLA-B*1502
F F F - F (carbamazepine) F
F F F F F F F
F F
. . F F F F
F F
(Drughypersensitivity) F F F
F F F
F F F
F F 2
F F F F , F
F F F F (Stevens-Johnson syndrome F F SJS)
F (toxic epidermal necrolysis F F TEN)
F F
F F F F F
F F F F 2-7 1 F F
25-80% F F F
F . F 0-2564-7000 F 1461,1462 e-mail : thaismc@nstda.or.th

2. F F F F F
F F F
F F F F F F F F F F F
F F F F F
F F F F F
. F F F
F . .2546
F
F F F
F F F F
F F F F F F
F F F F F F
F F HLA Human Leukocyte Antigen
HLA F F HLA F F F
HLA F3 F 1. F F
F F 2. F
F F 3. F F
F F F F F F F
. F F HLA F F F
F HLA HLA
F F F F F
F . F 0-2564-7000 F 1461,1462 e-mail : thaismc@nstda.or.th

3. F F
F F
F F F F F
200 F F 100
F F F A
F F
F 160 F G
F 40 F C
F F F F F F F A F F
50 F G F 150 F C F F
F F G F F F
F F F F
F HLA-B F F
F F F F HLA-B *1502
F F F HLA F
F F F F
F F F
F F F F F F
F F F F F
F F F F
! HLA-B*1502 F
F F F F F
F F F . .2549 F
F F F F F SJS/TEN
5 F F (Co-trimoxazole), F (carbamazepine),
(allopurinol), (Phenytoin) (amoxicilin)
WHO Uppsala Monitoring Center (WHO-UMC) F F
SJS TEN F !!
F F F F F F
F SJS TEN F F
F . F 0-2564-7000 F 1461,1462 e-mail : thaismc@nstda.or.th

4. HLA-B*1502 F F F F F F F
F F F F F
F F . . F
F . . F F F
F FF F F F
HLA-B F
F F F F F
F F ( .)
. .
F F F HLA-B
F SJS/TEN F
F F F SJS/TEN F
F F F F F F
F F F F 42 F
37 ( 88.1%) HLA-B*1502 F F F F
42 5 ( 11.9%) F
HLA-B*1502 F HLA-B*1502 F F
SJS/TEN F F F 55 F (sensitivity)
(specificity) F F HLA-B*1502
F 88.10% ( F F F Epilepsia, 2010; 51: 926-930)
F F F F
SJS/TEN (allopurinol) F F F F
F F F 27 SJS/TEN F (
100%) HLA-B*5801 7 54 ( 12.96%) F
HLA-B*5801 F F F F F HLA-B*5801
SJS/TEN 348 F (sensitivity) (specificity)
F F 100% 87%, ( F F
Pharmacogenetic and Genomics, 2009 ;19:704-9)
F F HLA-B F F
F F SJS/TEN F
F F F F F F
F . F 0-2564-7000 F 1461,1462 e-mail : thaismc@nstda.or.th

5. F F FF
F F F
. . F F F
F F F F F F
F F F
F F
F F F F F
F F F F F F F
F F
F F F F F
F F F F
http://pharmacology.md.kku.ac.th email pharmacogenomic.test.kku@gmail.com
23/06/53
///////////////////////////////////////////////
F . F 0-2564-7000 F 1461,1462 e-mail : thaismc@nstda.or.th